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AbstrAct
Objective to evaluate the magnitude of response to 
secukinumab treatment over 3 years in patients with 
ankylosing spondylitis (aS) grouped by baseline c-reactive 
protein (crP) levels in a pooled study of two pivotal phase 
iii studies: MeaSUre 1 (nct01358175) and MeaSUre 2 
(nct01649375).
Methods this post hoc analysis pooled data from all 
patients with available baseline crP in the two studies who 
received subcutaneous secukinumab 150  mg (approved 
dose; n=197) or placebo (n=195). assessed efficacy 
endpoints included assessments of Spondyloarthritis 
international Society (aSaS)20/40, Bath ankylosing 
Spondylitis Disease activity index (BaSDai), BaSDai50, aS 
Disease activity Score inactive disease and aSaS partial 
remission among patients grouped by baseline crP based 
on central laboratory cut-off <5  mg/l (normal) or ≥5  mg/l 
(elevated) and a cut-off <10  mg/l or ≥10  mg/l.
Results at baseline, 36.5% (143/392) patients had normal 
and 63.5% (249/392) had elevated crP. at week 16, 
aSaS20/40 response rates were higher for secukinumab 
versus placebo in normal (56.9%/34.7% vs 28.2%/7.0%; 
p<0.01/p<0.001) and in elevated (63.2%/42.4% vs 
29.0%/15.3%; both p<0.0001) crP groups. improvement 
was reported for all outcomes (p<0.05) in both groups, 
except for aSaS partial remission in the normal crP 
group, where a numerical difference 12.5% vs 2.8%, 
p=0.07) was observed. Similar trends of improvement 
were observed in the <10  and ≥10  mg/l groups across 
all efficacy outcomes at week 16. treatment responses to 
secukinumab in all crP groups further improved over 156 
weeks.
Conclusion Secukinumab 150  mg demonstrated rapid 
and sustained efficacy in patients with aS irrespective 
of baseline crP, with greater magnitude of response in 
patients with more elevated crP.
InTROduCTIOn
Constituting a major part of the spectrum of 
axial spondyloarthritis (axSpA), ankylosing 
spondylitis (AS) is a chronic inflammatory 
rheumatic disease characterised by irrevers-
ible structural damage of the sacroiliac joints 
and the spine, which is frequently associated 
with pain, stiffness, disability and reduced 
quality of life.1 2 Elevated levels of C-reac-
tive protein (CRP) in patients with AS is an 
important factor for the early detection of 
the disease.3 CRP is an item in the Assess-
ments of SpondyloArthritis international 
Society (ASAS) classification criteria, and is 
one of the key components of the AS Disease 
Activity Score (ASDAS). Elevated baseline 
CRP has also been described as a predictor of 
Key messages
What is already known about this subject?
 ► elevated baseline c-reactive protein (crP) has been 
described to be a predictor of treatment response 
to tumour necrosis factor inhibitors in patients with 
ankylosing spondylitis (aS).
What does this study add?
 ► this post hoc analysis showed that secukinumab 
150 mg provides rapid and sustained efficacy in 
patients with aS irrespective of baseline crP levels, 
with greater magnitude of response in patients with 
elevated crP.
 ► the results herein show that patients with normal 
baseline crP levels also have a strong likelihood of 
experiencing a positive treatment response with in-
terleukin-17a inhibition.
How might this impact on clinical practice?
 ► there was an unmet need for effective treatment 
strategies in patients with aS with normal baseline 
crP levels, and herein, we show that secukinumab 
works in patients with both normal and elevated crP 
levels, thus widening the spectrum of patients who 
could be treated effectively.
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treatment response to tumour necrosis factor inhibitors 
(TNFi) in patients with active AS.4–8
According to the ASAS-EULAR recommendations,9 
the first treatment of choice in patients with axSpA 
is non-steroidal anti-inflammatory drugs (NSAIDs), 
while conventional disease-modifying antirheumatic 
drugs (cDMARDs), according to the new nomencla-
ture proposed,10 are largely not efficacious.11 This is in 
contrast to biologic DMARDs, such as TNFi and interleu-
kin-17A (IL-17A) inhibitor, which are the only biologics 
that are currently recommended and approved for the 
management of AS.9 The baseline factors associated with 
TNFi treatment responses in patients with AS have been 
described by several authors.5–7 12 Among these, elevated 
baseline CRP levels is an important factor that predicts 
ASAS20 and ASAS40 responses, ASAS partial remission 
and Bath Ankylosing Spondylitis Disease Activity Index 
50 (BASDAI50) outcomes in patients with active AS 
treated with TNFi.6–8 12 13 Elevated CRP levels have also 
been shown to predict structural changes in patients with 
AS who treated with TNFi.13 However, the relationship 
between baseline CRP levels and the treatment response 
to IL-17A inhibition has not been assessed to date in 
patients with active AS. In addition, effective treatment 
strategies for patients with AS with normal baseline CRP 
levels are needed, as studies show response rates to TNFi 
are lower in patients with AS with normal CRP levels 
compared with those with elevated CRP levels.5 6 12–14
Secukinumab, a fully human monoclonal IgG1κ anti-
body that selectively neutralises IL-17A, significantly 
improved the signs and symptoms of active AS in the 
pivotal phase III MEASURE 1 and MEASURE 2 studies, 
with responses sustained over 3 years.15–18 Herein, we 
present a post hoc analysis that assessed the response to 
secukinumab treatment in patients with active AS, across 
normal and elevated baseline CRP levels in data pooled 
from the MEASURE 1 and MEASURE 2 studies over 3 
years.
MeTHOds
study design and patients
The MEASURE 1 (NCT01358175) and MEASURE 2 
(NCT01649375) study designs, eligibility criteria, meth-
odology and statistical analysis strategies have been 
described previously.15 Briefly, patients aged ≥18 years 
with AS, fulfilling the modified New York criteria,19 
with a score ≥4 (0–10 on the BASDAI,20 and spinal pain 
score ≥40 mm on (0–100 mm) the visual analogue scale, 
despite treatment with maximum tolerated doses of 
NSAIDs, were included in these studies. Patients treated 
with DMARDs and TNFi agents (other than sulfasala-
zine and methotrexate) were included with washout 
periods required before initiation of the study treatment. 
Patients treated with no more than one TNFi agent with 
an inadequate response to an approved dose for ≥3 
months or had unacceptable side effects with at least one 
dose were allowed to participate. Patients were allowed 
with the following concomitant medications at a stable 
dose: sulfasalazine (≤3 g per day), methotrexate (≤25 mg 
per week), prednisone or equivalent (≤10 mg per day) 
and NSAIDs. Key exclusion criteria were patients with 
total spinal ankylosis, evidence of infection or cancer 
on chest radiography, active systemic infection within 2 
weeks prior randomisation and previous treatment with 
cell-depleting therapies or biological agents other than 
TNFi agents. A flowchart of key inclusion and exclusion 
criteria of MEASURE 1 and 2 studies has been presented 
in online supplementary figure S1.
In MEASURE 1, patients received intravenous secuk-
inumab 10 mg/kg at baseline, weeks 2 and 4, followed 
by subcutaneous secukinumab 150 mg or 75 mg every 4 
weeks starting at week 8. Placebo was given on the same 
intravenous to subcutaneous dosing schedule. Based 
on the clinical response, placebo-treated patients were 
re-randomised to receive subcutaneous secukinumab 
150 mg or 75 mg at week 16 (ASAS20 non-responders) or 
week 24 (ASAS20 responders). In MEASURE 2, patients 
received subcutaneous secukinumab 150 mg, 75 mg or 
placebo at baseline, weeks 1, 2 and 3, followed by the 
same dose every 4 weeks starting at week 4. All place-
bo-treated patients were re-randomised to subcutaneous 
secukinumab 150 mg or 75 mg at week 16.
This post hoc analysis pooled data from all patients 
in the two studies (MEASURE 1 and 2) with available 
baseline CRP levels (patients with non-missing baseline 
CRP) who received subcutaneous secukinumab 150 mg 
(approved dose) or placebo. It has been reported that 
a CRP level above 5‒8 mg/L is the generally accepted 
cut-off for an abnormally high CRP, reflective of inflam-
mation in rheumatological disorders.13 14 21 22 A high-sensi-
tivity CRP (hsCRP) assay was performed in the MEASURE 
studies.23 24 The lower detection limit of CRP was 0.15 
mg/L (represents the lowest measurable CRP concen-
tration that can be distinguished from zero). Patients in 
this post hoc analysis were grouped by baseline CRP level 
as defined by the central laboratory (normal (<5 mg/L) 
or elevated (≥5 mg/L)) and by another clinically rele-
vant cut-off: CRP levels <10 mg/L or ≥10 mg/L. Patients 
in the elevated (≥5 mg/L CRP) group were further 
subdivided into the following ranges: ≥5 to <10 mg/L, 
≥10 to <15 mg/L and ≥15 mg/L (online supplementary 
data). Furthermore, to assess the proportion of patients 
who achieved early reduction in inflammation, patients 
were grouped based on whether or not they had a 50% 
decrease in CRP levels from baseline by week 4.
The studies were conducted in accordance with the 
Declaration of Helsinki.25
Outcome measures
Descriptions of the primary and secondary efficacy 
endpoints in the overall population in both studies 
have been published previously.15 Efficacy assessment in 
this analysis of pooled patients data through week 156 
included ASAS20, ASAS40, ASAS partial remission, mean 
change from baseline in total BASDAI score, BASDAI50 
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Table 1 Baseline demographic and clinical characteristics
Normal baseline CRP
(<5 mg/L)
Elevated baseline CRP
(≥5 mg/L)
Pooled secukinumab
150 mg (N=72)
Pooled placebo
(N=71)
Pooled secukinumab
150 mg (N=125)
Pooled placebo
(N=124)
Age (years), mean (SD) 42.3 (10.5) 45.3 (13.2) 39.9 (12.7) 42.2 (12.3)
Male, n (%) 39 (54.2) 47 (66.2) 91 (72.8) 93 (75.0)
Weight (kg), mean (SD) 74.5 (14.6) 76.4 (13.8) 79.2 (18.4) 79.0 (15.3)
Caucasian, n (%)* 50 (69.4) 51 (71.8) 88 (70.4) 100 (80.6)
Time since AS diagnosis (years), mean (SD) 5.9 (7.2) 8.1 (9.9) 7.2 (7.5) 7.3 (8.3)
Positive for HLA-B27, n (%) 44 (61.1) 53 (74.6) 99 (79.2) 95 (76.6)
TNFi-naïve, n (%) 52 (72.2) 39 (54.9) 84 (67.2) 94 (75.8)
Concomitant methotrexate use, n (%) 9 (12.5) 7 (9.9) 16 (12.8) 17 (13.7)
hsCRP (mg/L), median (minimum‒maximum) 2.1 (0.2‒4.9) 1.9 (0.2‒4.9) 16.8 (5.0‒237.0) 14.9 (5.0‒146.8)
Total BASDAI score, mean (SD) 6.7 (1.4) 6.6 (1.6) 6.3 (1.6) 6.6 (1.4)
PtGA of disease activity (0‒100 mm), mean 
(SD) †
68.0 (17.4) 66.9 (19.3) 63.7 (19.1) 68.4 (16.7)
*Race was self-assessed.
†Disease activity was scored on a visual-analog scale from 0 (no disease activity) to 100 mm (the most severe disease activity).
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HLA, human leucocyte antigen; N, 
number of patients in this pooled study; PtGA, patients global assessment; TNFi, tumor necrosis factor inhibitor; hsCRP, high sensitivity CRP.
(an improvement of at least 50% of the initial total 
BASDAI score) and ASDAS inactive disease (ASDAS 
<1.3).7 26–28 All efficacy outcomes were assessed in patients 
grouped by (1) normal and elevated baseline CRP levels 
(normal (<5 mg/L) or elevated (≥5 mg/L)), (2) base-
line CRP levels of <10 mg/L and ≥10 mg/L, (3) patients 
within subgroups by elevated CRP ranges and (4) patients 
with or without a 50% CRP decrease by week 4.
statistical analysis
The results are reported for patients originally randomised 
to subcutaneous secukinumab 150 mg (approved dose) 
or placebo. Statistical analyses used non-responder impu-
tation through week 16, multiple imputation (MI) from 
week 20 to 156 for binary variables and mixed-effect 
model repeated measure (MMRM) for all time points 
through week 156 for continuous variables. The statistical 
comparisons for binary variables (n, percentages, odds 
ratios, 95% CIs and p values) were performed using a 
logistic regression model with study, treatment and TNFi 
status as factors, and baseline score if appropriate (only 
BASDAI50 and ASDAS inactive disease had their baseline 
value) and weight as covariates. The continuous variables 
(least square mean±SE [LSM±SE], 95% CI and p values) 
used study, treatment, analysis visit, TNFi status as factors 
and weight and baseline values as continuous covariates. 
Treatment by analysis visit and baseline value by analysis 
visit were included as interaction terms in the model, for 
which an unstructured covariance structure was assumed.
ResulTs
A total of 392 patients with available baseline CRP values 
were pooled in this post hoc analysis of the two studies 
(MEASURE 1 and 2) from the secukinumab 150 mg 
(N=197) and placebo (N=195) groups. Of these, 36.5% 
(143/392) of patients had normal baseline CRP (<5 
mg/L) and 63.5% (249/392) of patients had elevated 
baseline CRP (≥5 mg/L). The proportion of patients 
with normal and elevated CRP was similar in the secuki-
numab 150 mg and placebo groups.
Baseline demographic and clinical characteristics of 
all patients in the normal (<5 mg/L) and elevated (≥5 
mg/L) CRP groups were balanced across the groups in 
this analysis, except for the proportion of TNFi-naïve, 
human leucocyte antigen (HLA)-B27-positive patients 
and hsCRP level. The mean age in the normal and elevated 
CRP groups was 43.8 and 41 years, respectively, and the 
mean time since AS diagnosis was 7.0 and 7.2 years. Base-
line BASDAI was comparable across these groups with 
different levels of baseline inflammation (mean BASDAI 
score was 6.7 and 6.4 in the normal and elevated CRP 
groups, respectively). Mean patients global assessment 
of disease activity was 67.4 and 66.0, the proportion of 
HLA-B27-positive patients was 67.8% and 77.9% and the 
proportion of TNFi-naïve patients was 63.6% and 71.5% 
in the normal and elevated CRP groups, respectively. As 
expected, the median hsCRP (mg/L) values were lower 
in the normal CRP (2.1 (0.2‒4.9)) group compared with 
the elevated CRP (16.1 (5.0‒237.0)) group. Baseline 
demographic and clinical characteristics in the secuki-
numab 150 mg and placebo groups by normal (<5 mg/L) 
and elevated (≥5 mg/L) CRP are shown in table 1.
efficacy
normal and elevated crP
The ASAS20 response rate at week 16 was 56.9% with 
secukinumab 150 mg compared with 28.2% with placebo 
(p<0.01) in the normal CRP group, and 63.2% vs 29.0% 
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Figure 1 Improvement in (A) ASAS20 and (B) ASAS40 response rates in patients with normal or elevated CRP at baseline 
through week 156. *p<0.0001; †p<0.001; §p<0.01; ‡p<0.05 vs placebo; missing values were imputed as non-response through 
week 16. MI presented from week 20 to 156 (shaded area) included n=56 and 103 in the normal baseline CRP and elevated 
baseline CRP groups, respectively. Data for secukinumab 150 mg and placebo at week 16, and for secukinumab 150 mg at 
week 156 are depicted. ASAS, Assessment of SpondyloArthritis international Society criteria; CRP, C-reactive protein; MI, 
multiple imputation; N, number of patients with available baseline CRP (normal or elevated) included in this pooled study 
through week 16; n, number of patients in this pooled study from week 20 to 156.
(p<0.0001) in the elevated CRP group (figure 1A). The 
ASAS40 response rate was 34.7% with secukinumab 150 
mg vs 7.0% with placebo (p<0.001) at week 16 in the 
normal CRP group and 42.4% vs 15.3% (p<0.0001) in 
the elevated CRP group (figure 1B). These responses 
were sustained or further improved with secukinumab 
treatment in both the normal and elevated CRP groups 
through week 156 (figure 1A,B).
The LSM change from baseline in the BASDAI score at 
week 16 in the normal and elevated CRP groups was −2.2 
and −2.4 with secukinumab 150 mg vs −1.0 and −0.6 with 
placebo (p<0.001 and p<0.0001), respectively (figure 2). 
A higher proportion of patients in the secukinumab 150 
mg (19.4%) group achieved ASDAS inactive disease than 
those in the placebo (4.2%; p<0.05) group at week 16 
in normal and 15.2% vs 2.4% (p<0.01), respectively, in 
elevated CRP groups (figure 3). These improvements in 
BASDAI score and ASDAS inactive disease response rates 
were sustained or further improved over 156 weeks of 
treatment with secukinumab 150 mg in both the normal 
and elevated CRP groups (figures 2 and 3).
BASDAI50 responses in the normal and elevated CRP 
groups were 27.8% and 39.2% with secukinumab 150 mg 
vs 7.0% and 10.5% with placebo (p<0.01 and p<0.0001), 
respectively. The ASAS partial remission response 
rate was 12.5% and 16.0% with secukinumab 150 mg 
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Figure 2 Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p<0.0001; 
†p<0.001; vs placebo; MMRM data shown through week 156. From week 20 to 156 data shown for n=56 and 103 patients in 
the normal baseline CRP and elevated baseline CRP groups, respectively. Data for secukinumab 150 mg and placebo at week 
16, and for secukinumab 150 mg at week 156 are depicted. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, 
C-reactive protein; MMRM, mixed-effect model repeated measure; N, number of patients with available baseline CRP (normal 
or elevated) included in this pooled study through week 16; n, number of patients in this pooled study from week 20 to 156.
vs 2.8% and 4.0% with placebo (p=0.07 and p<0.01) 
in the normal and elevated CRP groups, respectively, 
at week 16. These results were further improved after 
156 weeks of secukinumab treatment in both groups 
(BASDAI50: 40.4% and 60.6%; ASAS partial remission: 
14.4% and 32.1%, in normal and elevated CRP groups, 
respectively).
Efficacy outcomes in the additional groups by CRP 
ranges of ≥5 to <10 mg/L, ≥10 to <15 mg/L and ≥15 
mg/L showed higher responses in patients with higher 
CRP levels and are presented in online supplementary 
table S1.
Baseline crP levels of <10 mg/l and ≥10 mg/l
Overall, 54.1% (212/392) of patients had a CRP level 
<10 mg/L and 45.9% (180/392) had a CRP level ≥10 
mg/L. Efficacy outcomes in patients grouped by base-
line CRP levels <10 mg/L and ≥10 mg/L are presented 
in table 2. The ASAS20/40 response rate at week 16 was 
51.8%/33.6% with secukinumab 150 mg compared with 
29.4%/9.8% with placebo (p<0.01/0.001) in the <10 
mg/L group and 72.4%/47.1% vs 28.0%/15.1% (both 
p<0.0001) with secukinumab vs placebo in the ≥10 mg/L 
group. Similar improvements were observed in both 
groups for other efficacy endpoints at week 16, which 
were sustained or further improved over 156 weeks of 
secukinumab treatment (table 2).
efficacy in patients with or without a 50% decrease in baseline 
crP
A higher proportion (140/197 (71.1%)) of patients in the 
secukinumab 150 mg group reported a CRP decrease of 
50% from baseline at week 4 compared with the placebo 
(28/193 (14.5%)) group. The ASAS20 response rate at 
week 16 was 72.1% with secukinumab 150 mg compared 
with 35.7% with placebo (p<0.001) in patients with a 
50% CRP decrease, and the response rate was 33.3% vs 
27.9% (p=0.31) in patients without a 50% CRP decrease. 
Improvements across all other efficacy endpoints were 
observed at week 16 in patients with a 50% CRP decrease 
treated with secukinumab versus placebo, except for 
ASDAS inactive disease and ASAS partial remission 
response rates (table 3). These results were sustained or 
further improved after 156 weeks of secukinumab treat-
ment (table 3).
dIsCussIOn
Long-term (156-week) efficacy and safety results of 
secukinumab in AS from the MEASURE 1 and MEASURE 
2 studies have been reported previously.17 18 This report 
focuses on the pooled efficacy of secukinumab 150 mg 
over 3 years across both patients grouped by baseline CRP 
levels (<5 mg/L (normal) or ≥5 mg/L (elevated) and <10 
mg/L or ≥10 mg/L) and by the proportion of patients with 
a CRP decrease of 50% from baseline by week 4. In this 
W
alaeus Bibl./C1-Q64. Protected by copyright.
 o
n
 9 August 2019 at Leids Universitair M
edisch Centrum
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000749 on 21 Novem
ber 2018. Downloaded from
 
6 Braun J, et al. RMD Open 2018;4:e000749. doi:10.1136/rmdopen-2018-000749
RMD Open
Figure 3 Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. 
§p<0.01; ‡p<0.05 vs placebo; missing values were imputed as non-response through week 16. MI presented from week 20 to 
156 (shaded area) included n=56 and 103 in the normal baseline CRP and elevated baseline CRP groups, respectively. Data 
for secukinumab 150 mg and placebo at week 16 and for secukinumab 150 mg at week 156 are depicted. ASDAS, Ankylosing 
Spondylitis Disease Activity Score; CRP, C-reactive protein; MI, multiple imputation; N, number of patients with available 
baseline CRP (normal or elevated) included in this pooled study through week 16; n, number of patients in this pooled study 
from week 20 to 156.
Table 2 Clinical efficacy in patients grouped by baseline CRP levels: <10 mg/L and ≥10 mg/L
Week
Baseline CRP levels <10 mg/L Baseline CRP levels ≥10 mg/L
Pooled secukinumab
150 mg (N=110)
Pooled placebo
(N=102)
Pooled secukinumab
150 mg (N=87)
Pooled placebo
(N=93)
ASAS20, % 16 51.8** 29.4 72.4**** 28.0
156 63.0 – 83.3 –
ASAS40, % 16 33.6*** 9.8 47.1**** 15.1
156 44.5 – 70.3 –
BASDAI, mean change from 
baseline
16 −1.99**** −0.86 −2.78**** −0.62
156 −2.73 – −3.62 –
BASDAI50, % 16 30.0** 10.8 41.4**** 7.5
156 46.0 – 61.8 –
ASDAS inactive disease, % 16 20.0** 4.9 12.6* 1.1
156 28.9 – 15.6 –
ASAS partial remission, % 16 16.4** 2.9 12.6* 4.3
156 21.7 – 31.1 –
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs placebo; missing values were imputed as non-response at week 16. MI and MMRM data presented 
at week 156 included n=88 and 71 in baseline CRP levels <10 mg/L and ≥10 mg/L, respectively. For BASDAI, LS mean change from baseline was 
presented using MMRM at weeks 16 and 156.
ASAS, Assessment of SpondyloArthritis international Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; LS, least squares; MI, multiple imputation; MMRM, mixed-effect model 
repeated measures; N, number of patients included in this pooled study at week 16; n, number of patients in this pooled study at week 156.
post hoc analysis, secukinumab 150 mg showed improve-
ment across all efficacy endpoints by week 16 in patients 
with AS in both normal and elevated baseline CRP levels, 
with a greater magnitude of improvement observed in 
patients with elevated levels of baseline CRP, except for 
ASDAS inactive disease. A similar trend of improvement 
was also observed across all efficacy endpoints in patients 
grouped by baseline CRP <10 mg/L and ≥10 mg/L, 
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Table 3 Clinical efficacy in subgroups of patients with or without 50% CRP decrease from baseline by week 4
Week
With 50% CRP decrease by week 4 Without 50% CRP decrease by week 4
Pooled secukinumab
150 mg (N=140)
Pooled placebo
(N=28)
Pooled secukinumab
150 mg (N=57)
Pooled placebo
(N=165)
ASAS20, % 16 72.1*** 35.7 33.3 27.9
156 77.8 – 56.2 –
ASAS40, % 16 49.3** 14.3 15.8 12.1
156 64.1 – 32.3 –
BASDAI, mean change from 
baseline
16 −2.69**** −0.60 −1.34 −0.78
156 −3.42 – −2.22 –
BASDAI50, % 16 42.1** 10.7 17.5* 9.1
156 60.8 – 33.1 –
ASDAS inactive disease, % 16 21.4 0.0 5.3 3.6
156 25.3 – 16.6 –
ASAS partial remission, % 16 18.6 0.0 5.3 4.2
156 31.8 – 7.7 –
*p<0.05 ; **p<0.01; ***p<0.001; ****p<0.0001 vs placebo; missing values were imputed as non-response at week 16. MI and MMRM data presented 
at week 156 included n=120 and 39 with and without 50% CRP decrease by week 4, respectively. One placebo patient from each study (MEASURE 
1 and 2) did not included in the analysis of 50% CRP decrease by week 4 due to unavailability of the post baseline CRP value. For BASDAI, LS 
mean change from baseline was presented using MMRM at weeks 16 and 156.
ASAS, Assessment of SpondyloArthritis international Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; LS, least squares; MI, multiple imputation; MMRM, mixed-effect model 
repeated measures; N, number of patients included in this pooled study at week 16; n, number of patients in this pooled study at week 156.
except for ASDAS inactive disease. A higher proportion 
of secukinumab-treated patients with a CRP decreased by 
50% from baseline at week 4 reported improvement in 
all efficacy endpoints at week 16. All these improvements 
were sustained or further improved over 156 weeks of 
secukinumab treatment.
It has been reported that a higher CRP level is a 
predictor of improved ASAS20 and ASAS40 responses in 
patients with AS receiving TNFi therapy.6 12 In this pooled 
study, treatment response to secukinumab was not depen-
dent on baseline CRP level, with the majority of patients 
in the normal (57%), elevated (63%), <10 mg/L (52%) 
and ≥10 mg/L (72%) baseline CRP groups achieving an 
ASAS20 response by 16 weeks of secukinumab treatment. 
The ASAS40 responders at week 16 were comparable 
across these groups: normal (35%), elevated (42%), <10 
mg/L (34%) and ≥10 mg/L (47%). These responses 
improved across all baseline CRP groups through long-
term (156 week) secukinumab treatment. This analysis 
shows that patients with normal baseline CRP levels also 
have a strong likelihood of experiencing a positive treat-
ment response with IL-17A inhibition.
Improvement of the ASDAS composite index 
measuring disease activity has been associated with 
elevated baseline CRP level in patients receiving TNFi 
therapy.29 Individual items in the BASDAI and baseline 
CRP level are components of the ASDAS composite 
index and, therefore, are used to determine ASDAS inac-
tive disease response rate.30 In our study, 19% of patients 
with normal and 15% of patients with elevated baseline 
CRP attained ASDAS inactive disease status with secuki-
numab at week 16. Similarly, the change in BASDAI score 
was −2.2 in the normal CRP and −2.4 in the elevated CRP 
groups with secukinumab treatment at week 16. Compa-
rable results were also reported in patients with baseline 
CRP <10 mg/L and ≥10 mg/L groups for ASDAS inactive 
disease status and BASDAI score. These findings further 
confirm that attaining ASDAS inactive disease status and 
improvement in BASDAI score with secukinumab treat-
ment is not dependent on having an elevated baseline 
CRP value, as improvements were seen across the full 
patient spectrum, regardless of baseline levels of inflam-
mation. This is in contrast to previous studies of TNFi 
therapies in patients with AS.31–35 However, it is possible 
that the number of patients with normal CRP at baseline 
treated in prior studies with TNFi was too low to show 
significant response rates. A recent study in non-radio-
graphic axSpA showed that patients treated with the 
TNFi who had normal CRP values, and no MRI findings 
at baseline had ASAS40 response rates of 42% with TNFi 
vs 25% with placebo (p=0.264).36 Nevertheless, regula-
tory authorities currently request that patients in non-ra-
diographic axSpA studies have either an abnormal CRP 
and/or positive MRI findings at baseline for the purposes 
of inclusion.
The BASDAI50 response rate in secukinumab-treated 
patients was higher (39%) in the elevated baseline 
CRP group versus the normal group (28%) at week 
16. Similarly, in the higher hurdle efficacy endpoint of 
ASAS partial remission, a higher proportion (16%) of 
patients in the elevated baseline CRP group responded 
at week 16, which was further improved (32%) by week 
156, compared with the patients with normal baseline 
CRP (13% at week 16% and 14% at week 156). These 
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response rates in secukinumab-treated patients were 
more comparable across the baseline CRP <10 mg/L 
and ≥10 mg/L groups at week 16. Thus, while it is not 
exclusively required for responsiveness to secukinumab 
treatment, an elevated baseline CRP level has a positive 
influence on efficacy in signs and symptoms in AS. These 
results with IL-17A-inhibition are in-line with research 
suggesting that elevated baseline CRP is a predictor of 
improvements in BASDAI50 and ASAS partial remission 
in patients with AS on TNFi therapy.7 12 37
Achieving at least a 50% decrease in CRP by week 4 was 
analysed as a key threshold, since the average group-level 
reduction in CRP levels in the MEASURE 1 and 2 studies 
with secukinumab treatment was 50%.15 In patients with 
at least a 50% CRP decrease by week 4, the ASAS20 
response rate at week 16 was 72% compared with 33% 
in patients with less than a 50% CRP decrease. Similar 
trends of improvement in patients with at least a 50% 
CRP decrease by week 4 were observed across all efficacy 
endpoints at week 16, which were sustained or further 
improved over 156 weeks of secukinumab treatment. The 
results of our study suggest that an early reduction of CRP 
levels may be a predictor of treatment response to secuki-
numab. Conversely, patients showing a <50% decrease in 
CRP at week 4 are less likely to respond to secukinumab 
at week 16. To what extent those patients could benefit 
from an increased dose of secukinumab after week 4 is 
an open question. It remains to be seen whether higher 
doses of secukinumab may be able to reduce CRP levels 
further in these patients and/or lead to greater improve-
ments in AS signs and symptoms. The 300 mg dose of 
secukinumab is being evaluated in AS in ongoing clinical 
studies. However, although reflective of an association 
between CRP level, inflammation and clinical symptoms, 
the thresholds of CRP reduction assessed in this study 
may not reflect consistently reproducible clinical pheno-
types and, therefore, need to be explored further.
A limitation of this post hoc analysis is that the MEASURE 
1 and MEASURE 2 studies did not stratify randomisation 
by baseline CRP level. In addition, although a hsCRP 
assay was used, detection of a 50% drop in CRP values 
would be more challenging in patients with normal base-
line CRP values (<5 mg/L) due to detection limits of the 
laboratory assay. Other design limitations include the lack 
of a comparator group beyond week 16 and the fact that, 
although originally randomised treatment groups were 
blinded in these studies up to week 104, the nature of the 
study designs determined that patients and investigators 
were aware that all patients received secukinumab from 
week 16 onward, which may have introduced systematic 
bias in the reporting of results.
In conclusion, secukinumab 150 mg provided sustained 
long-term improvement over 3 years in multiple clinical 
domains in a mixed population of patients with AS with 
or without increased baseline CRP level, who were either 
naïve or had responded inadequately to TNFi treatment. 
While a substantial percentage of patients with normal 
baseline CRP values can respond to secukinumab, the 
magnitude of response is higher in patients with increased 
baseline CRP. Inclusion of prospectively planned anal-
yses by baseline CRP level in future clinical trials would 
help guide treatment strategies for patients with AS with 
normal, as well as elevated, baseline CRP.
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